Oster rediscovered - Mega-dose folate for symptomatic atherosclerosis

Medical Hypotheses

Volumn 69, Issue 2, 2007, Pages 325-332

  McCarty, Mark F ^a  

^a NutriGuard Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLTETRAHYDROPTERIN; FOLIC ACID; NITRIC OXIDE SYNTHASE; PLASMALOGEN; XANTHINE OXIDASE;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CASE REPORT; DRUG MEGADOSE; ENDOTHELIUM; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK ASSESSMENT; SYMPTOMATOLOGY; THEORY; TREATMENT DURATION; WOUND HEALING;

ANIMALS; ATHEROSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLIC ACID; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS;

ANGINA; BOVINAE;

EID: 34249318440     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.11.049     Document Type: Article

References (96)

1. Oster K.A., Ross D.J., and Dawkins H.H.R. The XO factor (1983), Park City Press, New York
2. Oster K.A., and Mulinos M.G. Tissue aldehydes and their reactions with amines. J Pharmacol Exp Ther 80 (1944) 132-138
3. Stadelmann-Ingrand S., Favreliere S., Fauconneau B., Mauco G., and Tallineau C. Plasmalogen degradation by oxidative stress: production and disappearance of specific fatty aldehydes and fatty alpha-hydroxyaldehydes. Free Radic Biol Med 31 (2001) 1263-1271
4. Zoeller R.A., Grazia T.J., LaCamera P., Park J., Gaposchkin D.P., and Farber H.W. Increasing plasmalogen levels protects human endothelial cells during hypoxia. Am J Physiol Heart Circ Physiol 283 (2002) H671-H679
5. Engelmann B. Plasmalogens: targets for oxidants and major lipophilic antioxidants. Biochem Soc Trans 32 (2004) 147-150
6. Oster K.A. Role of plasmalogen in heart diseases. Recent Adv Stud Cardiac Struct Metab 1 (1972) 803-813
7. Ross D.J., and Oster K.A. Digestion and absorption of bovine milk xanthine oxidase. J Nutr 108 (1978) 1039-1042
8. Ross D.J., Sharnick S.V., and Oster K.A. Liposomes as a proposed vehicle for the persorption of bovine xanthine oxidase. Proc Soc Exp Biol Med 163 (1980) 141-145
9. Oster K.A., Oster J., and Ross D.J. Immune response to bovine xanthine oxidase in atherosclerotic patients. Am Lab (1974) 41-47
10. Oster K.A. Treatment of angina pectoris according to a new theory of its origin. Cardiol Digest (1968) 29-34
11. Kalckar H.M., and Klenow H. J Biol Chem 172 (1948) 349-350
12. Boss G.R., Ragsdale R.A., Zettner A., and Seegmiller J.E. Failure of folic acid (pteroylglutamic acid) to affect hyperuricemia. J Lab Clin Med 96 (1980) 783-789
13. Spector T., and Ferone R. Folic acid does not inactivate xanthine oxidase. J Biol Chem 259 (1984) 10784-10786
14. Oster K.A. The absorption and inhibition of xanthine oxidase. Am Lab (1976) October
15. Oster K.A. Atherosclerosis treated with folic acid. FASEB J (1981) 40
16. Oster K.A. Cholesterol and CHD. Circulation 60 (1979) 463-464
17. Oster K.A. Duplicity in a committee report on diet and coronary heart disease. Am Heart J 99 (1980) 409-412
18. Oster K.A. Dietary cholesterol and atherosclerosis: the Tarahumara (flying feet) Indians. Am J Clin Nutr 34 (1981) 1167-1170
19. Oster K.A. The egg controversy: are eggs good or bad. Am J Clin Nutr 36 (1982) 1259-1262
20. Stamler J. The coronary drug project - findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv Exp Med Biol 82 (1977) 52-75
21. Cutler J.A., Neaton J.D., Hulley S.B., Kuller L., Paul O., and Stamler J. Coronary heart disease and all-causes mortality in the multiple risk factor intervention trial: subgroup findings and comparisons with other trials. Prev Med 14 (1985) 293-311
22. Berry C.E., and Hare J.M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555 (2004) 589-606
23. Nishino T., and Tsushima K. Interaction of milk xanthine oxidase with folic acid. Inhibition of milk xanthine oxidase by folic acid and separation of the enzyme into two fractions on Sepharose 4B/folate gel. J Biol Chem 261 (1986) 11242-11246
24. Ho C.Y., and Clifford A.J. Digestion and absorption of bovine milk xanthine oxidase and its role as an aldehyde oxidase. J Nutr 106 (1976) 1600-1609
25. Clifford A.J., Ho C.Y., and Swenerton H. Homogenized bovine milk xanthine oxidase: a critique of the hypothesis relating to plasmalogen depletion and cardiovascular disease. Am J Clin Nutr 38 (1983) 327-332
26. Ho C.Y., and Clifford A.J. Bovine milk xanthine oxidase, blood lipids and coronary plaques in rabbits. J Nutr 107 (1977) 758-766
27. Chanarin I. Adverse effects of increased dietary folate. Relation to measures to reduce the incidence of neural tube defects. Clin Invest Med 17 (1994) 244-252
28. Berlin H., Berlin R., and Brante G. Oral treatment of pernicious anemia with high doses of vitamin B12 without intrinsic factor. Acta Med Scand 184 (1968) 247-258
29. Lederle F.A. Oral cobalamin for pernicious anemia. Medicine's best kept secret. JAMA 265 (1991) 94-95
30. Hathcock J.N., and Troendle G.J. Oral cobalamin for treatment of pernicious anemia. JAMA 265 (1991) 96-97
31. Oakley G.P.J., Adams M.J., and Dickinson C.M. More folic acid for everyone, now. J Nutr 126 (1996) 751S-755S
32. Verhaar M.C., Stroes E., and Rabelink T.J. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 22 (2002) 6-13
33. Stroes E.S., van Faassen E.E., Yo M., Martasek P., Boer P., Govers R., et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 86 (2000) 1129-1134
34. Hyndman M.E., Verma S., Rosenfeld R.J., Anderson T.J., and Parsons H.G. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 282 (2002) H2167-H2172
35. Milstien S., and Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 263 (1999) 681-684
36. Kohnen S.L., Mouithys-Mickalad A.A., Deby-Dupont G.P., Deby C.M., Lamy M.L., and Noels A.F. Oxidation of tetrahydrobiopterin by peroxynitrite or oxoferryl species occurs by a radical pathway. Free Radic Res 35 (2001) 709-721
37. Kuzkaya N., Weissmann N., Harrison D.G., and Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 278 (2003) 22546-22554
38. Cosentino F., and Luscher T.F. Tetrahydrobiopterin and endothelial function. Eur Heart J 19 Suppl G (1998) G3-G8
39. Vasquez-Vivar J., Kalyanaraman B., Martasek P., Hogg N., Masters B.S., Karoui H., et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 95 (1998) 9220-9225
40. Katusic Z.S. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role?. Am J Physiol Heart Circ Physiol 281 (2001) H981-H986
41. Vasquez-Vivar J., Kalyanaraman B., and Martasek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic Res 37 (2003) 121-127
42. Stroes E., Kastelein J., Cosentino F., Erkelens W., Wever R., Koomans H., et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 99 (1997) 41-46
43. Maier W., Cosentino F., Lutolf R.B., Fleisch M., Seiler C., Hess O.M., et al. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol 35 (2000) 173-178
44. Heitzer T., Brockhoff C., Mayer B., Warnholtz A., Mollnau H., Henne S., et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : evidence for a dysfunctional nitric oxide synthase. Circ Res 86 (2000) E36-E41
45. Setoguchi S., Mohri M., Shimokawa H., and Takeshita A. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J Am Coll Cardiol 38 (2001) 493-498
46. Fukuda Y., Teragawa H., Matsuda K., Yamagata T., Matsuura H., and Chayama K. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart 87 (2002) 264-269
47. Setoguchi S., Hirooka Y., Eshima K., Shimokawa H., and Takeshita A. Tetrahydrobiopterin improves impaired endothelium-dependent forearm vasodilation in patients with heart failure. J Cardiovasc Pharmacol 39 (2002) 363-368
48. Higashi Y., Sasaki S., Nakagawa K., Fukuda Y., Matsuura H., Oshima T., et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens 15 (2002) 326-332
49. Fukuda Y., Teragawa H., Matsuda K., Yamagata T., Matsuura H., and Chayama K. Tetrahydrobiopterin improves coronary endothelial function, but does not prevent coronary spasm in patients with vasospastic angina. Circ J 66 (2002) 58-62
50. Ueda S., Matsuoka H., Miyazaki H., Usui M., Okuda S., and Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol 35 (2000) 71-75
51. Kaufman S. Some metabolic relationships between biopterin and folate: implications for the "methyl trap hypothesis". Neurochem Res 16 (1991) 1031-1036
52. Verhaar M.C., Wever R.M., Kastelein J.J., van Dam T., Koomans H.A., and Rabelink T.J. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 97 (1998) 237-241
53. Doshi S.N., McDowell I.F., Moat S.J., Lang D., Newcombe R.G., Kredan M.B., et al. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide. Arterioscler Thromb Vasc Biol 21 (2001) 1196-1202
54. Van Etten R.W., De Koning E.J., Verhaar M.C., Gaillard C.A., and Rabelink T.J. Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 45 (2002) 1004-1010
55. Doshi S.N., McDowell I.F., Moat S.J., Payne N., Durrant H.J., Lewis M.J., et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circ 105 (2002) 22-26
56. Wilmink H.W., Stroes E.S., Erkelens W.D., Gerritsen W.B., Wever R., Banga J.D., et al. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol 20 (2000) 185-188
57. Verhaar M.C., Wever R.M., Kastelein J.J., van Loon D., Milstien S., Koomans H.A., et al. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Circ 100 (1999) 335-338
58. Gori T., Burstein J.M., Ahmed S., Miner S.E., Al-Hesayen A., Kelly S., et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circ 104 (2001) 1119-1123
59. Mangoni A.A., Sherwood R.A., Swift C.G., and Jackson S.H. Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial. J Intern Med 252 (2002) 497-503
60. Pena A.S., Wiltshire E., Gent R., Hirte C., and Couper J. Folic acid improves endothelial function in children and adolescents with type 1 diabetes. J Pediatr 144 (2004) 500-504
61. Cooke J.P., and Oka R.K. Atherogenesis and the arginine hypothesis. Curr Atheroscler Rep 3 (2001) 252-259
62. Maxwell A.J., Anderson B.E., and Cooke J.P. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med 5 (2000) 11-19
63. Vermeulen E.G., Stehouwer C.D., Twisk J.W., van den B.M., de Jong S.C., Mackaay A.J., et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 355 (2000) 517-522
64. Oster K.A. A cardiologist considers psoriasis. Cutis 20 (1977) 39-40 45
65. Er-raki A., Charveron M., and Bonafe J.L. Increased superoxide anion production in dermal fibroblasts of psoriatic patients. Skin Pharmacol 6 (1993) 253-258
66. Yildirim M., Inaloz H.S., Baysal V., and Delibas N. The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 17 (2003) 34-36
67. Baz K., Cimen M.Y., Kokturk A., Yazici A.C., Eskandari G., Ikizoglu G., et al. Oxidant/antioxidant status in patients with psoriasis. Yonsei Med J 44 (2003) 987-990
68. Frank S., Kampfer H., Podda M., Kaufmann R., and Pfeilschifter J. Identification of copper/zinc superoxide dismutase as a nitric oxide-regulated gene in human (HaCaT) keratinocytes: implications for keratinocyte proliferation. Biochem J 346 Pt 3 (2000) 719-728
69. Ornish D. Avoiding revascularization with lifestyle changes: the multicenter lifestyle demonstration project. Am J Cardiol 82 (1998) 72T-76T
70. McCarty M.F. A shift in myocardial substrate, improved endothelial function, and diminished sympathetic activity may contribute to the anti-anginal impact of very-low-fat diets. Med Hypotheses 62 (2004) 62-71
71. Boger R.H., Bode-Boger S.M., Thiele W., Creutzig A., Alexander K., and Frolich J.C. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 32 (1998) 1336-1344
72. Bednarz B., Wolk R., Chamiec T., Herbaczynska-Cedro K., Winek D., and Ceremuzynski L. Effects of oral l-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. Int J Cardiol 75 (2000) 205-210
73. Maxwell A.J., Zapien M.P., Pearce G.L., MacCallum G., and Stone P.H. Randomized trial of a medical food for the dietary management of chronic, stable angina. J Am Coll Cardiol 39 (2002) 37-45
74. Schwartz L. Amelioration of microvascular angina with arginine supplementation. Ann Intern Med 138 (2003) 160
75. Sicuteri F., Franchi G., Fanciullacci M., Giotti A., and Guidotti A. [Anti-anginous effect of a non-coronaro-dilator sulfurated amino acid]. Clin Ter 49 (1969) 205-219
76. Zanelli G., Ferrero S., and Patrone P. Taurine in the therapy of obliterating arteriopathy of the lower extremities. I. Clinical results in various evolutive phases. Minerva Cardioangiol 19 (1971) 605-615
77. McCarty M.F. The reported clinical utility of taurine in ischemic disorders may reflect a down-regulation of neutrophil activation and adhesion. Med Hypotheses 53 (1999) 290-299
78. Cherchi A., Lai C., Angelino F., Trucco G., Caponnetto S., Mereto P.E., et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled cross-over study. Int J Clin Pharmacol Ther Toxicol 23 (1985) 569-572
79. Fernandez C., and Proto C. L-carnitine in the treatment of chronic myocardial ischemia. An analysis of 3 multicenter studies and a bibliographic review. Clin Ter 140 (1992) 353-377
80. Lagioia R., Scrutinio D., Mangini S.G., Ricci A., Mastropasqua F., Valentini G., et al. Propionyl-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. Int J Cardiol 34 (1992) 167-172
81. Bartels G.L., Remme W.J., Holwerda K.J., and Kruijssen D.A. Anti-ischaemic efficacy of L-propionylcarnitine-a promising novel metabolic approach to ischaemia. Eur Heart J 17 (1996) 414-420
82. Brevetti G., Chiariello M., Ferulano G., Policicchio A., Nevola E., Rossini A., et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 77 (1988) 767-773
83. Brevetti G., Perna S., Sabba C., Martone V.D., and Condorelli M. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 26 (1995) 1411-1416
84. Brevetti G., Diehm C., and Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 34 (1999) 1618-1624
85. Barker G.A., Green S., Askew C.D., Green A.A., and Walker P.J. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Med Sci Sports Exerc 33 (2001) 1415-1422
86. Castano G., Mas R., Roca J., Fernandez L., Illnait J., Fernandez J.C., et al. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology 50 (1999) 123-130
87. Castano G., Mas F.R., Fernandez L., Gamez R., Illnait J., and Fernandez C. A long-term study of policosanol in the treatment of intermittent claudication. Angiology 52 (2001) 115-125
88. Castano G., Mas R., Fernandez L., Gamez R., and Illnait J. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. Angiology 54 (2003) 25-38
89. Castano G., Mas R., Gamez R., Fernandez L., and Illnait J. Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study. Angiology 55 (2004) 361-371
90. Stusser R., Batista J., Padron R., Sosa F., and Pereztol O. Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients. Int J Clin Pharmacol Ther 36 (1998) 469-473
91. Peters H., Kieser M., and Holscher U. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication - a placebo-controlled, double-blind multicenter trial. Vasa 27 (1998) 106-110
92. Pittler M.H., and Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med 108 (2000) 276-281
93. Kamikawa T., Kobayashi A., Yamashita T., Hayashi H., and Yamazaki N. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 56 (1985) 247-251
94. Tran M.T., Mitchell T.M., Kennedy D.T., and Giles J.T. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 21 (2001) 797-806
95. Tawakol A., Migrino R.Q., Aziz K.S., Waitkowska J., Holmvang G., Alpert N.M., et al. High-dose folic acid acutely improves coronary vasodilator function in patients with coronary artery disease. J Am Coll Cardiol 45 (2005) 1580-1584
96. Moat S.J., Clarke Z.L., Madhavan A.K., Lewis M.J., and Lang D. Folic acid reverses endothelial dysfunction induced by inhibition of tetrahydrobiopterin biosynthesis. Eur J Pharmacol 530 (2006) 250-258